Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study.

Abstract

Recently, it has been shown that FCGR3A-158 gene polymorphism is associated with biological and possibly clinical response to infliximab in Crohn's disease. We further assessed this association in a subset of 344 patients from the large and well-defined cohort of 573 patients with Crohn's disease from the ACCENT I study. No association could be observed between FCGR3A-158 gene polymorphism and the clinical response to infliximab, which was primarily defined as a decrease of >or=70 points in the Crohn's disease activity index or clinical remission (Crohn's disease activity index <150). We did, however, confirm a trend towards a greater decrease in C-reactive protein after infliximab in V/V homozygotes as compared with V/F heterozygotes and F/F homozygotes (-79.4, -76.5, and -64.3%, respectively, at week 6; P=0.085; one-tailed P=0.043). This finding has no immediate clinical impact but may enhance the understanding of the complex mechanisms of action of anti-tumor necrosis factor agents in Crohn's disease.

• Authors: Edouard J Louis, Hervé E Watier, Stefan Schreiber, Jochen Hampe, François Taillard, Allan Olson, Nicole Thorne, Hongyan Zhang, Jean-Frédéric Colombel
• Journal: Pharmacogenetics and genomics (Pharmacogenet Genomics) Vol. 16 Issue 12 Pg. 911-4 (Dec 2006) ISSN: 1744-6872 [Print] United States
• PMID: 17108815 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• DNA Primers
• FCGR3A protein, human
• Receptors, IgG
• Infliximab

Topics

• Adolescent
• Adult
• Aged
• Antibodies, Monoclonal (therapeutic use)
• Base Sequence
• Crohn Disease (genetics, immunology, therapy)
• DNA Primers (genetics)
• Female
• Genotype
• Heterozygote
• Homozygote
• Humans
• Infliximab
• Male
• Middle Aged
• Pharmacogenetics
• Polymorphism, Single Nucleotide
• Receptors, IgG (genetics)